KR20230046792A - COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Piperis Nigri Fructus - Google Patents
COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Piperis Nigri Fructus Download PDFInfo
- Publication number
- KR20230046792A KR20230046792A KR1020210130261A KR20210130261A KR20230046792A KR 20230046792 A KR20230046792 A KR 20230046792A KR 1020210130261 A KR1020210130261 A KR 1020210130261A KR 20210130261 A KR20210130261 A KR 20210130261A KR 20230046792 A KR20230046792 A KR 20230046792A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- streptococcus
- biofilm formation
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 title claims abstract description 33
- 230000032770 biofilm formation Effects 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 13
- 229940034610 toothpaste Drugs 0.000 claims description 9
- 239000000606 toothpaste Substances 0.000 claims description 9
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229940051866 mouthwash Drugs 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002324 mouth wash Substances 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 241001135221 Prevotella intermedia Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 241000194019 Streptococcus mutans Species 0.000 claims description 4
- 241000194024 Streptococcus salivarius Species 0.000 claims description 4
- 241000193987 Streptococcus sobrinus Species 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims description 3
- 241000589996 Campylobacter rectus Species 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 3
- 241001135235 Tannerella forsythia Species 0.000 claims description 3
- 241000589892 Treponema denticola Species 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 241000588878 Eikenella corrodens Species 0.000 claims description 2
- 241001464887 Parvimonas micra Species 0.000 claims description 2
- 241001135225 Prevotella nigrescens Species 0.000 claims description 2
- 241001494431 [Eubacterium] nodatum Species 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 229940042125 oral ointment Drugs 0.000 claims description 2
- 229940041678 oral spray Drugs 0.000 claims description 2
- 239000000668 oral spray Substances 0.000 claims description 2
- 239000002966 varnish Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 241000589886 Treponema Species 0.000 claims 1
- 208000025157 Oral disease Diseases 0.000 abstract description 6
- 208000030194 mouth disease Diseases 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 235000008184 Piper nigrum Nutrition 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000013588 oral product Substances 0.000 abstract 1
- 235000020744 piper nigrum extract Nutrition 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 7
- 208000002925 dental caries Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 239000007621 bhi medium Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 206010006326 Breath odour Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 241000009298 Trigla lyra Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- -1 brighteners Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000002170 dentin sensitivity Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 호초 추출물을 유효성분으로 포함하는 바이오필름 형성 억제용 조성물에 관한 것이다.The present invention relates to a composition for inhibiting biofilm formation comprising Hocho extract as an active ingredient.
치아우식증(dental cavities, 충치) 및 치주질환(periodontal disease, 풍치)은 통증, 저작기능 장애, 치주조직의 파괴, 구취 및 시린이와 같은 다양한 임상적인 증상을 유발하고 치아상실을 초래하는 주된 요인으로 알려져 있으며, 식생활의 변화로 이러한 구강질환의 원인요소는 더 증가하고 있는 실정이다.Dental cavities (cavities) and periodontal disease (periodontal disease) cause various clinical symptoms such as pain, masticatory dysfunction, destruction of periodontal tissues, bad breath and cold teeth, and are the main factors that cause tooth loss. It is known, and the causative factors of these oral diseases are increasing due to changes in dietary life.
사람의 구강에는 대략 600 내지 800종 이상의 미생물이 존재하는 것으로 알려져 있는데, 이러한 미생물들은 타액이 분비하는 리소자임(lysozyme)과 같은 효소에 의해 제어되고 있다. 그러나 영양분과 수분이 풍부한 구강환경은 미생물이 성장하기 좋은 조건이며, 혀나 치태(dental plaque)는 미생물의 훌륭한 서식처를 제공한다. 이러한 미생물 중 일부는 기회병원성 균으로서 치아우식, 치주질환 및 시린이(상아질 지각과민증)과 같은 질환 및 구취의 원인이 된다.It is known that about 600 to 800 or more microorganisms exist in the human oral cavity, and these microorganisms are controlled by enzymes such as lysozyme secreted by saliva. However, the oral environment rich in nutrients and moisture is a favorable condition for the growth of microorganisms, and the tongue or dental plaque provides an excellent habitat for microorganisms. Some of these microorganisms are opportunistic pathogens and cause diseases such as dental caries, periodontal disease, and tooth decay (dentin hypersensitivity) and bad breath.
한편, 바이오필름(biofilm)은 생물막이라고도 불리며, 미생물이 세포 주위에 다당체를 생산하고 이것을 매개로 인접한 미생물과 응집하여 고체나 생체 표면에 막(film)을 형성하고 있는 상태를 의미한다. On the other hand, a biofilm is also called a biofilm, and means a state in which microorganisms produce polysaccharides around cells and aggregate with adjacent microorganisms through this to form a film on a solid or biological surface.
바이오필름 형성은 치아 우식증, 세균성 심내막염, 만성 부비동염, 식중독, 폐렴 등과 같이 여러 질병의 발병(pathogenesis)에 중요한 역할을 하는 것으로 알려져 있다.Biofilm formation is known to play an important role in the pathogenesis of various diseases such as dental caries, bacterial endocarditis, chronic sinusitis, food poisoning, and pneumonia.
특히, 치아 우식증과 같은 구강 질환은 병원균이 치면에 플라크(바이오필름)를 형성함으로써 구강 내에 정착하여 병원성을 발휘한다. 따라서, 구강 질환의 예방 및 치료에는 이러한 바이오필름의 컨트롤이 매우 중요하게 여겨진다.In particular, in oral diseases such as dental caries, pathogens settle in the oral cavity by forming plaque (biofilm) on the tooth surface to exhibit pathogenicity. Therefore, the control of these biofilms is considered very important for the prevention and treatment of oral diseases.
이러한 이유로 부작용이 적은 천연물 유래 예방 및/또는 치료제 개발은 필수적이며 계속적인 연구가 필요한 상태이다.For this reason, the development of natural product-derived preventive and/or therapeutic agents with fewer side effects is essential and requires continuous research.
본 발명자들은 부작용이 적은 천연물 유래 바이오필름 형성 억제제를 개발하고자 예의 연구 노력하였다. 그 결과, 호초(Piperis Nigri Fructus)이 바이오필름 형성을 억제하는 능력이 우수한 것을 확인함으로써, 본 발명을 완성하였다.The present inventors have made intensive research efforts to develop natural product-derived biofilm formation inhibitors with fewer side effects. As a result, the present invention was completed by confirming that Piperis Nigri Fructus has an excellent ability to inhibit biofilm formation.
따라서, 본 발명의 목적은 호초(Piperis Nigri Fructus) 추출물을 유효성분으로 포함하는 바이오필름 형성 억제용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for inhibiting biofilm formation comprising an extract of Hocho ( Piperis Nigri Fructus ) as an active ingredient.
본 발명의 다른 목적은 호초 추출물을 유효성분으로 포함하는 구강용 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to provide a quasi-drug composition for oral use containing Hocho extract as an active ingredient.
본 발명자들은 부작용이 적은 천연물 유래 바이오필름 형성 억제제를 개발하고자 예의 연구 노력하였다. 그 결과, 호초(Piperis Nigri Fructus)이 바이오필름 형성을 억제하는 능력이 우수한 것을 확인하였다.The present inventors have made intensive research efforts to develop natural product-derived biofilm formation inhibitors with fewer side effects. As a result, it was confirmed that Hocho ( Piperis Nigri Fructus ) has excellent ability to inhibit biofilm formation.
본 발명은 호초 추출물을 유효성분으로 포함하는 바이오필름 형성 억제용 조성물 및 구강용 의약외품 조성물에 관한 것이다.The present invention relates to a composition for inhibiting biofilm formation and a quasi-drug composition for oral use containing an extract of Hochoe as an active ingredient.
본 발명은 호초(Piperis Nigri Fructus) 추출물을 이용하여 티타늄 표면에서 바이오필름의 형성 억제 효능에 있어서 유의미한 결과를 확인하였다.In the present invention, significant results were confirmed in the inhibitory effect of biofilm formation on the titanium surface using the extract of Hocho (Piperis Nigri Fructus) .
이하, 본 발명을 더욱 자세히 설명하고자 한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 양태에 따르면, 본 발명은 호초(Piperis Nigri Fructus) 추출물을 유효성분으로 포함하는 바이오필름 형성 억제용 조성물에 관한 것이다.According to one aspect of the present invention, the present invention relates to a composition for inhibiting biofilm formation comprising an extract of Piperis Nigri Fructus as an active ingredient.
본 발명에서, "호초(Piperis Nigri Fructus)"는 후추과 호초(piper nigrium)의 성숙에 가까운 과실로, 가을부터 다음 봄 사이 과실이 암녹색을 띨 때 채취하여 건조한 것으로, 호초에서 추출한 호초기름은 리놀렌산이 많이 들어있어 동맥경화 등 순환기계통의 질병과 치료에 탁월한 효과가 있는 것으로 보고되었으나, 바이오필름 형성 억제 활성에 대해서는 전혀 보고된 바 없었다.In the present invention, " Piper nigri Fructus " is a fruit close to maturity of Piper nigrium, which is collected and dried when the fruit is dark green from autumn to next spring. Hocho oil extracted from Hocho is linolenic acid It has been reported to have an excellent effect on diseases and treatment of circulatory system such as arteriosclerosis, but there has been no report on biofilm formation inhibitory activity.
본 명세서에서 사용되는 용어 '추출물'은 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 호초 추출물은 상술한 추출 용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 호초 추출물에 포함되는 것이다.The term 'extract' used herein has a meaning commonly used in the art as a crude extract, but also includes a fraction obtained by further fractionating the extract in a broad sense. That is, the Hocho extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method are also included in the hocho extract of the present invention.
본 발명의 호초 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The hocho extract of the present invention can be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
본 발명에서, 추출 용매는 물, 및 탄소수 1 내지 4개의 직쇄 또는 분지형 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트, 1,3-부틸렌 글리콜, 헥산 및 디에틸에테르로 이루어진 군에서 선택된 1종 이상의 용매인 것일 수 있으나, 이에 한정되는 것은 아니다. In the present invention, the extraction solvent is at least one selected from the group consisting of water, straight chain or branched alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, 1,3-butylene glycol, hexane and diethyl ether It may be a solvent, but is not limited thereto.
본 발명에서, 추출 온도는 예를 들어 0 ℃내지 150 ℃일 수 있으며, 구체적으로는 50 ℃내지 100 ℃일 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the extraction temperature may be, for example, 0 °C to 150 °C, specifically 50 °C to 100 °C, but is not limited thereto.
본 발명에서, 추출 시간은 예를 들어 1시간 내지 10 시간일 수 있으며, 구체적으로는 3 시간 내지 8시간일 수 있고, 더욱 구체적으로는 5 시간 내지 7 시간일 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the extraction time may be, for example, 1 hour to 10 hours, specifically 3 hours to 8 hours, and more specifically 5 hours to 7 hours, but is not limited thereto.
본 발명의 호초 추출물은 공지의 천연물 추출법으로 추출될 수 있다. 예를 들어 냉침 추출, 열수 추출, 초음파 추출, 환류냉각 추출, 가열 추출법으로 추출할 수 있으며, 구체적으로는 열수 추출 또는 환류 냉각 추출법으로 추출할 수 있으며, 1회 내지 10회, 보다 구체적으로는 2회 내지 7회 반복 추출할 수 있다.Hocho extract of the present invention can be extracted by a known natural product extraction method. For example, it can be extracted by cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, and heating extraction. Specifically, it can be extracted by hot water extraction or reflux cooling extraction, 1 to 10 times, more specifically 2 Extraction can be repeated 7 times to 7 times.
본 발명에서, 상기 바이오필름 형성 억제용 조성물은 상기 호초 추출물을 1 mg/ml의 농도로 포함할 수 있다.In the present invention, the composition for inhibiting biofilm formation may include the Hocho extract at a concentration of 1 mg/ml.
본 발명에서, "바이오필름(biofilm)"은 미생물이 표면에 축척하여 세포와 결합되어 있는 다량의 고분자 화합물과 표면에 부착되는 유기물, 무기물로 이루어진 얇은 막을 의미하며, 생물막과 상호 교환적으로 사용될 수 있다. 바이오필름 내의 세균은 부유상태보다 항생물질에 대한 내성이 10 배 내지 1000배 이상 증가될 수 있으며, 세균의 형질이 변해서 세포외 다당물질이나 산소에 의해 항생물질이 불활성화 되거나, 바이오필름 형성으로 인해 성장속도를 늦추어 내성을 획득하게 된다.In the present invention, "biofilm" refers to a thin film composed of a large amount of macromolecular compounds in which microorganisms accumulate on the surface and are associated with cells, and organic substances and inorganic substances attached to the surface, and can be used interchangeably with biofilms. there is. Bacteria in biofilms can increase their resistance to antibiotics 10 to 1000 times more than in the suspended state, and the morphology of bacteria is changed so that antibiotics are inactivated by extracellular polysaccharide or oxygen, or by biofilm formation. It slows growth and acquires tolerance.
상기 바이오필름은 포르피로모나스 진지발리스(Porphyromonas gingivalis), 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans), 탄네렐라 포르시티아(Tannerella forsythia), 트레포네마 덴티콜라(Treponema denticola), 프레보텔라 니그레센스(Prevotella nigrescens), 유박테리움 노다툼(Eubacterium nodatum), 파르비모나스 미크라(Parvimonas micra), 아이케넬라 코로덴스(Eikenella corrodens), 캄필로박터 렉투스(Campylobacter rectus), 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum), 스트렙토코쿠스 소브리누스(Streptococcus sobrinus), 스트렙토코쿠스 살리바리우스(Streptococcus salivarius), 스트렙토코쿠스 안지나서스(Streptococcus anginasus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 및 프레보텔라 인터메디아(Prevotella intermedia)로 이루어진 군에서 선택되는 미생물에 의하여 형성된 것일 수 있으나, 이에 제한되는 것은 아니다.The biofilm is Porphyromonas gingivalis ( Porphyromonas gingivalis ), Aggregatibacter actinomycetem comitans ( Aggregatibacter actinomycetemcomitans ), Tannerella forsythia ( Tannerella forsythia ), Treponema denticola ( Treponema denticola ), Prevotella nigrescens , Eubacterium nodatum, Parvimonas micra , Eikenella corrodens, Campylobacter rectus , Fusobacterium nucleatum ( Fusobacterium nucleatum ), Streptococcus sobrinus ( Streptococcus sobrinus ), Streptococcus salivarius ( Streptococcus salivarius ), Streptococcus anginasus ( Streptococcus anginasus ), Streptococcus mutans ( Streptococcus mutans ) and Prevotella intermedia ( Prevotella intermedia ) It may be formed by a microorganism selected from the group consisting of, but is not limited thereto.
본 발명에서, "바이오필름 형성 억제"는 바이오필름의 형성 속도를 감소시키는 것을 의미하며, 이는 상기 바이오필름 형성 미생물, 즉 구강 세균의 배양 시작 시점으로부터 단위시간 당 미생물의 생균 수 증가율 감소를 의미한다. 상기 미생물의 생균 수는 배양 이후 나타난 미생물의 집락 수를 세어 측정할 수 있으며, mL 당 생균 수(CFU/mL)로 나타낼 수 있다.In the present invention, "inhibition of biofilm formation" means to reduce the rate of biofilm formation, which means a decrease in the rate of increase in the number of viable cells per unit time from the start of the culture of the biofilm-forming microorganisms, that is, oral bacteria. . The number of viable cells of the microorganisms may be measured by counting the number of colonies of the microorganisms appearing after culturing, and may be expressed as the number of viable cells per mL (CFU/mL).
본 발명의 다른 일 양태에 따르면, 본 발명은 호초 추출물을 유효성분으로 포함하는 구강용 의약외품 조성물에 관한 것이다.According to another aspect of the present invention, the present invention relates to a quasi-drug composition for oral cavity comprising a Hocho extract as an active ingredient.
본 발명의 의약외품 조성물에 포함되는 성분은 유효성분으로서 상기 유효성분 이외에 구강용 의약외품 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 연마제, 습윤제, 결합제, 기포제, 감미제, 방부제, 약효성분, 향미제, 색소, 용제, 증백제, 가용화제 또는 pH 조정제를 포함할 수 있다.Ingredients included in the quasi-drug composition of the present invention may include ingredients commonly used in oral quasi-drug compositions in addition to the above active ingredients as active ingredients, such as abrasives, wetting agents, binders, foaming agents, sweeteners, preservatives, medicinal ingredients, flavors agents, pigments, solvents, brighteners, solubilizers or pH adjusters.
본 발명의 구강용 의약외품 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 치약, 구강세정제, 구강청정제, 껌, 캔디류, 구강스프레이, 구강용 연고제, 구강용 바니쉬, 구강양치액 및 잇몸 마사지 크림 등의 제형을 가질 수 있으나 이에 제한되는 것은 아니다.The quasi-drug composition for oral use of the present invention can be prepared in any formulation commonly prepared in the art, for example, toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral ointment, and oral varnish. , oral rinse and gum massage cream, but may have formulations such as, but are not limited thereto.
하나의 예로서, 본 발명의 구강용 의약외품 조성물이 치약의 제형일 경우, 습윤제, 연마제, 결합제, 기포제, 향미제, 감미제, 착색제, 보존제, 약효성분, 용제, pH 조절제 등을 포함할 수 있다.As an example, when the oral quasi-drug composition of the present invention is a toothpaste formulation, it may contain a wetting agent, an abrasive, a binder, a foaming agent, a flavoring agent, a sweetening agent, a coloring agent, a preservative, a medicinal component, a solvent, a pH adjusting agent, and the like.
상기 습윤제는 치약제 성분 중 분말이 페이스트상이 되게 하고 치약제가 공기 중에 굳는 것을 방지하기 위한 것으로 글리세린, 솔비트액, 프로필렌글리콜, 폴리에틸렌 글리콜 등을 단독 또는 2종 이상 혼합하여 조성물 총 중량 중 1 ~ 60 중량%, 구체적으로는 10 ~ 50 중량%를 사용할 수 있다.The humectant is to make the powder of toothpaste ingredients paste and prevent the toothpaste from hardening in the air, and glycerin, sorbitol, propylene glycol, polyethylene glycol, etc. alone or in combination of two or more, 1 to 60 weight of the total weight of the composition %, specifically, 10 to 50% by weight may be used.
상기 기포제는 치약제를 구강 중에 확산시켜 청소효과를 높이고, 계면활성제로서 작용하여 구강 오염을 세정하는 것으로 라우릴황산나트륨, 라우릴 사르코신산 나트륨, 알킬 설포호박산 나트륨, 자당 지방산 에스테르 등의 계면활성제를 단독 혹은 2종 이상 혼합하여 조성물 총 중량 중 0.5 ~ 10 중량%, 구체적으로는 0.5 ~ 5 중량%를 사용할 수 있다.The foaming agent diffuses the toothpaste into the oral cavity to increase the cleaning effect and acts as a surfactant to clean oral contamination. Alternatively, 0.5 to 10% by weight, specifically 0.5 to 5% by weight of the total weight of the composition may be used by mixing two or more kinds.
상기 결합제는 치약제중의 분말과 액체 성분 간의 분리를 방지하는 것으로 카복시메틸셀룰로오스나트륨, 메틸셀룰로오스, 하이드록시 프로필셀룰로오스 등의 셀룰로오스 유도체와 알긴산나트륨, 카라기난, 잔탄검 등을 단독 혹은 2종 이상 혼합하여 조성물 총 중량 중 0.1 ~ 5 중량%, 구체적으로는 0.3 ~ 2 중량%를 사용할 수 있다.The binder prevents separation between powder and liquid components in toothpaste, and is a mixture of cellulose derivatives such as sodium carboxymethyl cellulose, methyl cellulose, and hydroxypropyl cellulose, sodium alginate, carrageenan, xanthan gum, etc. alone or in combination of two or more. 0.1 to 5% by weight, specifically 0.3 to 2% by weight of the total weight of the composition may be used.
상기 연마제는 치아표면을 상처내지 않고 치아표면의 부착물을 제거하고 치아 본래의 광택이 나도록 하는 것으로 탄산칼슘(CaCO3), 제2인산칼슘(CaHPO4, CaHPO42H2O), 무수규산(SiO22H2O), 수산화알루미늄(Al(OH)3), 피로인산카륨, 탄산마그네슘 등을 단독 혹은 2종 이상 혼합하여 조성물 총 중량 중 1 ~ 60 중량%, 구체적으로는 10 ~ 50 중량%를 사용할 수 있다.The abrasive is calcium carbonate (CaCO 3 ), calcium phosphate dibasic (CaHPO 4 , CaHPO 4 2H 2 O), silicic anhydride (SiO 2 2H 2 O), aluminum hydroxide (Al(OH) 3 ), potassium pyrophosphate, magnesium carbonate, etc. alone or in combination of two or more, and 1 to 60% by weight, specifically 10 to 50% by weight of the total weight of the composition can be used
상기 향미제는 치약에 상쾌감과 냄새를 부여하여 사용감을 증진시키기 위한 것으로 페퍼민트오일, 스피아민트오일, 멘톨 등을 단독 혹은 2종 이상 혼합하여 조성물 총 중량 중 1 ~ 60 중량%, 구체적으로는 0.01 ~ 5 중량%를 사용할 수 있다.The flavoring agent is to enhance the feeling of use by imparting a refreshing feeling and smell to the toothpaste, and peppermint oil, spearmint oil, menthol, etc. alone or in combination of two or more are used in an amount of 1 to 60% by weight, specifically 0.01 to 60% by weight of the total weight of the composition. 5% by weight can be used.
상기 감미제는 치약제 원료에 의한 불쾌한 맛이나 제거하고 청량감을 좋게 하기 위한 것으로 사카린산, 아스파탐, 자일리톨, 감초산 등을 단독 혹은 2종 이상 혼합하여 조성물 총 중량 중 1 ~ 60 중량%, 구체적으로는 0.01 ~ 5 중량%를 사용할 수 있다.The sweetener is to remove the unpleasant taste caused by raw materials for toothpaste and improve the refreshing feeling, and 1 to 60% by weight of the total weight of the composition by mixing saccharic acid, aspartame, xylitol, licorice acid, etc. alone or in combination of two or more, specifically 0.01 to 5% by weight can be used.
약효성분은 치우 우식증 예방, 치주질환 예방, 치통 예방, 시린이 예방, 구취 제거 등의 효과를 위한 것으로 불화물, 염화아연, 클로르헥시딘, 아미노카프론산, 트라넥사민산, 염화세틸피리디움, 염화피리독신, 트리클로산, 초산토코페롤, 일불소인산나트륨 등을 단독 혹은 2종 이상 혼합하여 사용할 수 있다. 본 발명에서는 포르시토사이드 비를 추가적인 약효성분으로 사용할 수 있다.The active ingredients are for the prevention of dental caries, periodontal disease, toothache prevention, cold lice prevention, bad breath removal, etc. Triclosan, tocopherol acetate, sodium monofluorophosphate, etc. may be used alone or in combination of two or more. In the present invention, forsitoside ratio can be used as an additional active ingredient.
본 발명의 구강용 의약외품 조성물은 단독 또는 중복하여 사용하거나, 본 발명 이외의 다른 구강용 의약외품 조성물과 중복하여 사용할 수 있다.The quasi-drug composition for oral use of the present invention may be used alone or in combination, or may be used in combination with other quasi-drug compositions for oral use other than the present invention.
본 발명의 또 다른 일 양태에 따르면, 본 발명은 호초 추출물을 유효성분으로 포함하는 구강용 식품 조성물에 관한 것이다. 상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다.According to another aspect of the present invention, the present invention relates to a food composition for oral cavity containing a Hocho extract as an active ingredient. The food composition may be used in the form of health functional food, but is not limited thereto.
본 발명의 식품 조성물에 포함된 상기 추출물은 이의 분획물 또는 이의 가공물의 형태로 포함될 수 있다. 또한 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The extract included in the food composition of the present invention may be included in the form of a fraction thereof or a processed product thereof. In addition, the composition may include a food additive that is acceptable in food science in addition to the active ingredient.
본 발명에서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, "food supplement additive" refers to a component that can be added to food supplementally, and can be appropriately selected and used by those skilled in the art as being added to prepare a health functional food of each formulation. Examples of food additives include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.
본 발명에서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 구강질환을 예방 또는 개선시키기 위한 보조제로 섭취가 가능하다.In the present invention, "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functionalities for the human body. Here, "functionality" means obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation. In addition, the formulation of the health functional food may also be manufactured without limitation as long as the formulation is recognized as a health functional food. The food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time using food as a raw material, and has excellent portability, so that the composition of the present invention Health functional food can be consumed as a supplement to prevent or improve oral diseases.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 포르시토사이드 비를 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.There is no limit to the form that the health functional food of the present invention can take, and it can include all foods in a conventional sense, and can be used interchangeably with terms known in the art, such as functional foods. In addition, the health functional food of the present invention can be prepared by mixing suitable other auxiliary ingredients and known additives that can be included in food according to the selection of those skilled in the art. Examples of food that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes, etc., and it can be prepared by adding the forsitoside ratio according to the present invention to juice, tea, jelly, juice, etc. prepared as a main component. It also includes food used as feed for animals.
본 발명은 호초 추출물을 유효성분으로 포함하는 바이오필름 형성 억제용 조성물에 관한 것으로, 본 발명에 따른 호초 추출물을 사용하는 경우 구강 세균의 번식 및 바이오필름 형성을 억제할 수 있는 바, 각종 구강용품, 구강질환 치료제 등의 개발에 유용하게 사용될 수 있다.The present invention relates to a composition for inhibiting biofilm formation comprising a Hocho extract as an active ingredient. It can be usefully used for the development of oral disease treatment, etc.
도 1은 본 발명의 일 실시예에 따른 본 발명의 호초 추출물의 바이오필름 형성 억제능 평가 결과를 나타낸다.
도 2는 본 발명의 일 실시예에 따른 본 발명의 호초 추출물의 바이오필름 형성 억제능 평가 결과를 나타낸다.1 shows the evaluation results of the biofilm formation inhibitory ability of the Hocho extract of the present invention according to an embodiment of the present invention.
Figure 2 shows the evaluation results of the biofilm formation inhibitory ability of the Hocho extract of the present invention according to an embodiment of the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
모든 실험의 결과는 Mean±Standard error로 표기하였고, 실험자료의 통계 분석은 Student's t-test로 하였으며, p 값이 0.001 미만일 때 통계적으로 유의한 것으로 판단하였다.The results of all experiments were expressed as Mean±Standard error, and the statistical analysis of the experimental data was performed with Student's t-test, and it was judged to be statistically significant when the p value was less than 0.001.
실험예 1. 호초 추출물의 바이오필름 형성 억제 효과 평가Experimental Example 1. Evaluation of biofilm formation inhibitory effect of Hocho extract
실험에 사용된 호초(Piperis Nigri Fructus) 열수 추출물(23.2 mg/mL)은 한국 식물 추출물 은행(Korea Plant Extract Bank, KPEB)으로부터 제공받았으며, 호초 추출물의 분양번호는 CW04-080이다.Hocho ( Piperis Nigri Fructus ) hot water extract (23.2 mg/mL) used in the experiment was provided by the Korea Plant Extract Bank (KPEB), and the distribution number of Hocho extract is CW04-080.
티타늄 디스크(지름 10 mm, Dentium) 위에 여과한 타액(saliva)을 200μl씩 뿌려준 후 ∞ 모양으로 살살 흔들어주었다. 4 시간 동안 37 ℃에서 인큐베이션한 후, 타액을 제거하였다.After spraying 200 μl of filtered saliva on a titanium disk (10 mm in diameter, Dentium), it was gently shaken in an ∞ shape. After incubation at 37° C. for 4 hours, saliva was removed.
P. gingivalis(ATCC 33277, KCOM) 500 μL를 BHI 배지(BHI, Hemin 5 μg/mL, Vitamin K1 1 μg/mL) 9.5 mL에 넣고 24 시간 동안 37 ℃에서 배양한 후, 배양액을 1.5 mL e-tube에 1 mL씩 담고 12,000 rpm에서 3 분 동안 원심분리하였다. 상층액을 버린 후, BHI 배지 1 mL를 첨가하여 펠릿(pellet)을 풀어주었다. 그 다음, 20 μL를 따서 BHI 배지 380 μL에 1/20로 희석하였다. 희석한 배양액 200 μL를 96-웰 플레이트에 넣고, OD600을 측정하였다. 측정된 OD600 값을 바탕으로, 1Х108 CFU/mL로 하기의 방법을 이용하여 P. gingivalis의 투입 부피(input volume)를 계산하였다.Add 500 μL of P. gingivalis (ATCC 33277, KCOM) to 9.5 mL of BHI medium (BHI, Hemin 5 μg/mL, Vitamin K1 1 μg/mL) and incubate at 37 °C for 24 hours. Each 1 mL was put into a tube and centrifuged at 12,000 rpm for 3 minutes. After discarding the supernatant, 1 mL of BHI medium was added to release the pellet. Then, 20 μL was taken and diluted 1/20 in 380 μL of BHI medium. 200 μL of the diluted culture medium was put into a 96-well plate, and OD 600 was measured. Based on the measured OD 600 value, the input volume of P. gingivalis was calculated at 1Х10 8 CFU/mL using the following method.
[1mL 안에 들어있는 P. gingivalis의 총 CFU, 원액][Total CFU of P. gingivalis in 1 mL, stock solution]
= {7156.4(0.204; OD희석값 - 0.086; OD 배지) - 20.258= {7156.4 (0.204; OD dilution value - 0.086; OD medium) - 20.258
= (824.1972 X 106 CFU/mL) X 20= (824.1972 X 10 6 CFU/mL) X 20
= 16483.944 X 106 CFU/mL= 16483.944 X 10 6 CFU/mL
= 164.83944 X 108 CFU/mL= 164.83944 X 10 8 CFU/mL
이때, 전체 부피가 4 mL(4 개의 디스크에 1 mL씩 접종)라 할 때, 투입 부피(하기 X)는,At this time, when the total volume is 4 mL (1 mL inoculated on 4 disks), the input volume (X below) is,
X μL = (1Х108 CFU/mL)/(164.83944 Х 108 CFU/mL) Х 4 mLX μL = (1Х10 8 CFU/mL)/(164.83944 Х 10 8 CFU/mL) Х 4 mL
= (1Х108 CFU/mL)/(164.83944 Х 108 CFU/mL) Х 4,000 μL= (1Х10 8 CFU/mL)/(164.83944 Х 10 8 CFU/mL) Х 4,000 μL
= 24.2660373027...= 24.2660373027...
= 24.27 μL= 24.27 µL
또한, 하기 계산식 1을 사용하여 호초 추출물의 투입 부피를 계산하였다.In addition, the input volume of the Hocho extract was calculated using the following formula 1.
[계산식 1][Calculation 1]
BHI 배지 4 mL에서, 상기에서 계산된 P. gingivlais의 투입 부피인 24.27 μL 및 호초 추출물의 투입 부피인 10.78 μL(1 mg/mL)를 각각 제거하였다. 각 부피가 제거된 배지에 상기에서 준비된 티타늄 디스크, P. gingivlais 배양액 24.27 μL 및 호초 추출물(1 mg/mL) 10.78 μL를 각각 첨가한 뒤, 볼텍싱(vortexing)을 진행하였다. 그 다음, 24-웰 플레이트의 각 웰에 1 mL씩 넣고 ∞모양으로 살살 흔들어주었다. 37 ℃의 혐기성 챔버(anaerobic chamber, Whitley DG 250 Workstation 230v/50Hz; 80% N2, 10% CO2 및 10% H2 and N2 100%)에서 72 시간 동안 인큐베이션하였다.In 4 mL of BHI medium, 24.27 μL, the input volume of P. gingivlais calculated above, and 10.78 μL (1 mg/mL), the input volume of Hocho extract, were respectively removed. The titanium disc prepared above, 24.27 μL of P. gingivlais culture medium, and 10.78 μL of Hocho extract (1 mg/mL) were respectively added to the medium from which each volume was removed, followed by vortexing. Then, 1 mL was added to each well of the 24-well plate and gently shaken in an ∞ shape. It was incubated for 72 hours in an anaerobic chamber (anaerobic chamber, Whitley DG 250 Workstation 230v/50Hz; 80% N 2 , 10% CO 2 and 10% H 2 and N 2 100%) at 37 °C.
각 웰 내 배지를 흡인(suction)하고 DPBS로 2회 세척하였다. 차광하여 실온에서 10 분 동안 크리스탈 바이올렛(Crystal violet)으로 염색하였다. DPBS로 3회 세척하였다. 티타늄 디스크를 새로운 플레이트에 이동시킨 후 탈염색 버퍼(Destaining buffer)로 크리스탈 바이올렛을 녹이고, 24-웰 플레이트의 각 웰에 넣은 후 OD595를 측정하였다. 측정된 OD595 값을 바탕으로, 하기 계산식 2를 사용하여 대조군(control) 대비 바이오필름의 상대량(relative amount of biofilm)(%)을 계산하였다.Media in each well was aspirated and washed twice with DPBS. It was stained with crystal violet for 10 minutes at room temperature under light blocking. Washed 3 times with DPBS. After moving the titanium disk to a new plate, crystal violet was dissolved in a destaining buffer, put into each well of a 24-well plate, and OD 595 was measured. Based on the measured OD 595 value, the relative amount of biofilm (%) compared to the control group was calculated using Equation 2 below.
[계산식 2][Calculation 2]
도 1 및 2에서 확인할 수 있듯이, 1 mg/mL 농도 이상의 호초 추출물은 P.gingivalis의 바이오필름 형성을 억제한다.As can be seen in Figures 1 and 2, Hocho extract at a concentration of 1 mg / mL or more inhibits the biofilm formation of P. gingivalis .
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210130261A KR20230046792A (en) | 2021-09-30 | 2021-09-30 | COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Piperis Nigri Fructus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210130261A KR20230046792A (en) | 2021-09-30 | 2021-09-30 | COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Piperis Nigri Fructus |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230046792A true KR20230046792A (en) | 2023-04-06 |
Family
ID=85918245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210130261A KR20230046792A (en) | 2021-09-30 | 2021-09-30 | COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Piperis Nigri Fructus |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230046792A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200093514A (en) | 2017-11-30 | 2020-08-05 | 라이온 가부시키가이샤 | Oral biofilm formation inhibitor and oral composition |
-
2021
- 2021-09-30 KR KR1020210130261A patent/KR20230046792A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200093514A (en) | 2017-11-30 | 2020-08-05 | 라이온 가부시키가이샤 | Oral biofilm formation inhibitor and oral composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5017697B2 (en) | Antibacterial agent | |
JP2006199661A (en) | Coaggregation inhibitor | |
JP4112730B2 (en) | Antibacterial agent for oral cavity | |
KR102571768B1 (en) | Composition and health functional food containing Ligilactobacillus salivarius IDCC 3551 having inhibiting gum disease and halitosis ability | |
JP5480864B2 (en) | Antibacterial agent and oral composition containing the same | |
WO2004026273A1 (en) | Composition for oral use | |
KR102438800B1 (en) | Composition comtaining lactic acid fermented noni extract as active ingredient for prevention or treatment of oral disease | |
KR20140031512A (en) | Composition for treating oral disease and inhibiting halitosis comprising the extract of schizandra chinensis | |
KR20060006074A (en) | Material for inhibiting enamel decalcification | |
KR20230046792A (en) | COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Piperis Nigri Fructus | |
KR20230046760A (en) | Composition for preventing biofilm formation comprising extract of vitidis viniferae caulis | |
KR20230046772A (en) | Composition for preventing biofilm formation comprising extract of trigonellae semen | |
KR102269164B1 (en) | Composition for improvement of dental caries and periodontal disease using an extract of seeds of Phaseolus radiatus, etc. | |
KR20230046819A (en) | Composition for preventing biofilm formation comprising extract of vitidis viniferae caulis | |
KR20230046651A (en) | COMPOSITION FOR PREVENTING BIOFILM FORMATION COMPRISING EXTRACT OF Pharbitis nil | |
JP5744985B2 (en) | Antibacterial agent | |
KR20230046727A (en) | Composition for preventing biofilm formation comprising zinc salt | |
JP7433125B2 (en) | Oral antibacterial agent | |
KR102668737B1 (en) | AN ORAL COMPOSITION COMPRISING AN EXTRACT OF A HERBAL COMPOSITION CONTAINING Lophatherum gracile AND Lonicera japonica AS AN ACTIVE INGREDIENT, AND A METHOD FOR PREPARING THE SAME | |
KR102452255B1 (en) | Composition comprising deacetyl asperulosidic acid and/or asperulosidic acid as active ingredient for prevention or treatment of oral disease | |
KR102557352B1 (en) | Composition for Preventing or Treating Periodontal Disease Comprising Extracts of Rosa davurica Pall as Active Ingredient | |
KR20120139310A (en) | Oral composition for preventing or treating caries and periodontal disease | |
KR102511133B1 (en) | Composition for Inhibiting Biofilm Formation Comprising Extracts of Coptis chinensis | |
KR20180047703A (en) | Composition for prevention or treatment of oral disease comprising Nelumbo Nucifera extract | |
KR20180047704A (en) | Composition for prevention or treatment of oral disease comprising Scutellaria baicalensis extract |